An ecosystem of research universities clustered with biotechnology and pharmaceutical companies and support services create the “cluster effect” investors should look for when investing in life sciences real estate, according to a report titled, “Selecting cities for life sciences real estate in Europe,” by Olafur Margeirsson, head of Real Estate Research & Strategy – Europe ex-DACH with UBS Asset Management, Global Real Assets, which was published in the September issue of Institutional Real Estate Europe.
“Investing in cities that already have established life sciences real estate assets provides several strategic advantages. These locations offer a proven track record of collaborative success, reduced developmental delays and a supportive and established supply chain ecosystem,” says Margeirsson.
“Furthermore, the presence of mature clusters attracts additional investment. Ancillary businesses — from logistics and specialised consult
